8-K: Cero Therapeutics Secures $350K Convertible Note

Cero Therapeutics Holdings, Inc. has issued a $350,000 convertible promissory note to Keystone Capital Partners, LLC, with a potential to draw up to $1,000,000.

Summary

• Cero Therapeutics Holdings, Inc. entered into a material definitive agreement on April 8, 2026.
• The company issued and sold a convertible promissory note for a purchase price of $350,000, with a principal face value of $437,500.
• The note was issued to Keystone Capital Partners, LLC.
• The company may borrow up to an aggregate of $1,000,000 under the note.
• The note bears interest at 10% per annum and matures on April 9, 2027.
• The note is convertible into shares of the company's common stock at a conversion price of the lesser of $0.05 or 80% of the average of the 5 lowest intraday trading prices during the 20 days prior to conversion request, subject to adjustments and a 4.99% beneficial ownership limitation.
• The company is obligated to file a registration statement for the resale of shares issuable upon conversion.
• The issuance was made under Section 4(a)(2) of the Securities Act and Rule 506(b), exempting it from registration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides necessary capital, the terms suggest potential dilution and a discount, which are common but not ideal for existing shareholders.

Positives

• Secured $350,000 in immediate funding.
• Potential to access up to $1,000,000 in additional capital.
• Interest rate of 10% is a standard rate for such instruments.
• Conversion terms provide flexibility for the lender while setting a cap on the conversion price.
• The company has a clear path to register shares for resale, facilitating future liquidity for the lender.

Negatives

• The principal face value of the note ($437,500) is higher than the purchase price ($350,000), indicating a discount.
• The conversion price can be significantly lower than the stated $0.05 if market prices are low, leading to substantial dilution.
• The beneficial ownership limitation of 4.99% may require multiple conversions or adjustments.
• The company is obligated to file a registration statement, which incurs costs and administrative burden.

Risks

• Potential for significant dilution of existing shareholders' equity due to the conversion feature.
• The conversion price mechanism could lead to the issuance of a large number of shares if the stock price declines.
• The company's obligation to file a registration statement could be a burden if not managed efficiently.
• The note's maturity date of April 9, 2027, requires timely repayment or conversion.

Future Outlook

The company is obligated to file a registration statement on Form S-1 or S-3 for the resale of shares issuable upon conversion of the note. The note matures on April 9, 2027, and is convertible into common stock.

Industry Context

StockSavvy.ai notes that convertible notes are a common financing tool for biotechnology and early-stage companies, often used to bridge funding gaps between development milestones. The terms, including the discount and conversion price adjustment, are typical for this sector, reflecting the inherent risks and the need for capital.

Stakeholder Impact

• Shareholders: Potential for dilution of ownership percentage and earnings per share due to the conversion of the note into common stock, especially if conversion occurs at a low price.
• Lender (Keystone Capital Partners, LLC): Gains the right to convert the note into equity, with potential upside if the company's stock price increases, and a downside protection through the conversion price adjustment.
• Creditors: The company's debt load increases, though the convertible nature may be viewed favorably compared to traditional debt.

Next Steps

• The company must prepare and file a registration statement on Form S-1 or S-3 with the SEC.
• The lender may elect to convert the note into common stock at any time after issuance.
• The note matures on April 9, 2027.

Key Dates

Recommendation

The filing indicates a necessary capital raise through a convertible note, which provides immediate funding but also carries the risk of significant dilution. The terms are standard for a company in this stage, but without further operational or clinical updates, the potential for dilution warrants a cautious 'hold' recommendation until the impact of this financing on future growth and share count becomes clearer.

Keywords

Convertible Promissory Note, Cero Therapeutics Holdings, Keystone Capital Partners, Material Definitive Agreement, Form 8-K, Financing, SEC Filing, Delaware Corporation